Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0001295

Spironolacton für die Systemeignung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Spironolacton, 4-Pregnen-21-säure-17α-ol-3-on-7α-thiol-γ-lacton-7-acetat, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-en-21-carbonsäure-γ-lacton

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C24H32O4S
CAS-Nummer:
52-01-7
Molekulargewicht:
416.57
MDL-Nummer:
MFCD00082250
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831347
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

spironolactone

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

207-208 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChIKey

LXMSZDCAJNLERA-ZHYRCANASA-N

Angaben zum Gen

human ... NR3C2(4306)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Spironolactone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Spironolacton ist ein kompetitiver Aldosteron-Rezeptor-Antagonist. Wird als Kaliumsparendes Diuretikum verwendet.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

S1200000

Spironolacton, European Pharmacopoeia (EP) Reference Standard

1619006

Spironolacton, United States Pharmacopeia (USP) Reference Standard

1619017

Spironolacton-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

BP306

Spironolacton, British Pharmacopoeia (BP) Reference Standard

PHR2886

Spironolacton, pharmaceutical secondary standard, certified reference material

PHR2887

Spironolacton-verwandte Verbindung A, pharmaceutical secondary standard, certified reference material

PHR3135

Spironolacton-verwandte Verbindung C, pharmaceutical secondary standard, certified reference material

Piktogramme

Health hazard
GHS08

Signalwort

Danger

Gefahreneinstufungen

Carc. 2 - Repr. 1B - STOT RE 2

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Doson Chua et al.
Clinical cardiology, 33(10), 604-608 (2010-10-21)
Spironolactone is used in the treatment of cardiovascular disease, but is contraindicated in renal dysfunction due to the risk of hyperkalemia. It is not known if patients with end-stage renal disease (ESRD) on hemodialysis are at the same risk for
Deepani Rathnayake et al.
Skinmed, 8(6), 328-332 (2011-03-19)
Spironolactone has been used as a potassium-sparing diuretic for more than 30 years. It is a synthetic 17-lactone steroid and primarily acts as an aldosterone antagonist. Since the accidental discovery of its antiandrogenic effects, it has been used in the
Enrico Vizzardi et al.
The American journal of the medical sciences, 347(4), 271-276 (2013-11-08)
The purpose of this study is to evaluate long-term effects of spironolactone, an affordable and widely used aldosterone receptor blocker, in patients with heart failure (HF) and mild or no symptoms. The study is a single-blind, placebo-controlled, blinded endpoint, randomized
Allan Struthers et al.
Clinical cardiology, 31(4), 153-158 (2008-04-12)
Improved understanding of the adverse pharmacological properties of aldosterone has prompted investigation of the clinical benefits of blocking aldosterone at the receptor level. This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and
Oscar M P Jolobe
European journal of internal medicine, 24(4), 303-309 (2012-12-19)
The evolution of strategies for the use of spironolactone and its analogue, eplerenone, has, over the years, encompassed favourable modification of the natural history of symptomatic heart failure in subjects with subnormal left ventricular ejection fraction (LVEF), and mitigation of
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.